MedTrace Logo

A Study to Evaluate a Modified RNA Vaccine Against Influenza in Adults 18 Years of Age or Older

NCT05540522 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 45789

Last updated 2025-05-08

Study results available
· View outcomes & findings →

Summary

This is a Phase 3, randomized, observer-blinded study to evaluate the efficacy, safety, tolerability, and immunogenicity of a single dose of a quadrivalent influenza modRNA vaccine compared to licensed inactivated influenza vaccine in healthy adults 18 years of age and older.

Conditions

  • Influenza, Human

Interventions

BIOLOGICAL

Quadrivalent influenza modRNA vaccine

Quadrivalent influenza modRNA vaccine (single dose)

BIOLOGICAL

Quadrivalent influenza vaccine

Licensed quadrivalent influenza vaccine (single dose)

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-09-12
Primary Completion
2024-03-12
Completion
2024-03-12
FDA Drug
Yes

Countries

  • United States
  • Argentina
  • Chile
  • New Zealand
  • Philippines
  • South Africa

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05540522 on ClinicalTrials.gov